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MaOBJECTIVES The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan
With Short Time Contact for Reduction of Restenosis in Distal Arteries).
BACKGROUND The THUNDER trial was the ﬁrst study to investigate the treatment of femoropopliteal arteries with
a paclitaxel-coated balloon (PCB).
METHODS In 154 patients, femoropopliteal arteries were treated with PCB, with angioplasty with paclitaxel in contrast
medium, or no paclitaxel (control). The primary endpoint was 6-month late lumen loss (LLL). Secondary endpoints
included freedom from target lesion revascularization (TLR), binary restenosis rate, and amputation. The 5-year FU
compares outcomes in patients treated with PCB and control subjects. Additionally, LLL at 6 months and TLR up to 5-year
FU were analyzed in terms of sex and lesion length.
RESULTS Over the 5-year period, the cumulative number of patients with TLR remained signiﬁcantly lower in the PCB
group (21%) than in the control group (56%, p ¼ 0.0005). In the small group of patients with angiographic and duplex
sonographic follow-up, PCB was associated with a lower rate of binary restenosis (17% vs. 54%; p ¼ 0.04). No signs of
aneurysm formation or constrictive ﬁbrosis were detected. Whereas LLL at 6-month FU did not differ between men and
women in the PCB group, the TLR rate was lower in men than in women at 5-year FU. A beneﬁt of PCB treatment in terms
of LLL and TLR was seen independent of lesion length.
CONCLUSIONS The reduced TLR rate following PCB treatment was maintained over the 5-year FU period. No signs
of drug-related local vessel abnormalities were detected. (Thunder Trial—Local Taxan With Short Time Contact for
Reduction of Restenosis in Distal Arteries [THUNDER]; NCT00156624) (J Am Coll Cardiol Intv 2015;8:102–8) © 2015 by
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AB BR E V I A T I O N S
AND ACRONYM S
CM = contrast medium
CRF = case report form
FU = follow-up
LLL = late lumen loss
PCB = paclitaxel-coated
balloon
SAE = serious adverse event(s)
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103of 24 months (1,2,5,8). The patients of the THUNDER
Trial (Local Taxan With Short Time Contact for Reduc-
tion of Restenosis in Distal Arteries), a randomized
study investigating the efﬁcacy of PCB for restenosis
prevention in the femoropopliteal arteries, have now
been followed up for 5 years. The aim of this follow-
up (FU) was to evaluate the long-term efﬁcacy and
safety of local paclitaxel administration in terms of po-
tential complications such as development of aneu-
rysms or occurrences of thrombotic occlusion.SEE PAGE 109
TLR = target lesion
revascularizationMETHODS
OUTLINE OF THUNDER STUDY: DESIGN, STUDY PATIENTS,
AND 6- TO 24-MONTH FOLLOW-UP. The THUNDER
study was designed to investigate the effect of local
paclitaxel administration using a PCB on the reste-
nosis rate after peripheral arterial interventions.
A total of 154 patients were recruited and random-
ized in a multicenter trial. The target lesions had a
mean pre-dilation degree of stenosis of 90  9%
and a mean length of 7.4  6.5 cm. One group was
treated with PCB and standard nonionic contrast
medium (CM) (PCB group), a second group was
treated with plain old balloon angioplasty and
paclitaxel added to the CM (paclitaxel-in-CM group),
and a third group was treated with plain old bal-
loon angioplasty and standard nonionic CM (control
group).
The PCB were coated with paclitaxel at a dose
of 3 mg/mm2 of balloon surface embedded in a ma-
trix consisting of a small amount of the nonionic
contrast agent iopromide (10), referred to in the
literature as Paccocath coating (B. Braun Melsungen
AG, Berlin, Germany). The total paclitaxel dose
administered per patient ranged from 1 to 17 mg
(mean: 5 mg).
Details of the methods and 6-month and 2-year
FU results have been previously published (1).
DESIGN, PATIENTS, AND ENDPOINTS AT 5-YEAR
FOLLOW-UP. The outcome in the paclitaxel-in-CM
group did not differ signiﬁcantly from that in the
control group at 6- and 24-month FU (late lumen loss
[LLL]: 2.2  1.6 mm, p ¼ 0.14; target lesion revascu-
larization [TLR]: 40%, p ¼ 0.25). Therefore, only
control patients and those treated with PCB were
invited to a 5-year FU visit. No 5-year FU was con-
ducted in patients with >1 TLR, with femoropopliteal
bypass graft involving the target lesion, and with
amputations of the study leg up to 24-month FU.
Figure 1 presents a chart of the 5-year FU disposition
of the original THUNDER population.Patients underwent 5-year FU by clinical
observation. This was done during a visit to
the study center or, if patients could not
come to the study center, by telephone
interview. All patients were asked to com-
plete a questionnaire on their current health
status and on clinical events having occurred
since their last FU. If the patients consented,
any angiographies or duplex ultrasound ex-
aminations conducted after the 24-month
follow-up, which included the target lesion
and allowed its evaluation, were included in
the 5-year FU analysis.
Clinical endpoints at 5-year FU included TLR, ma-
jor amputation of the treated leg as well as death.
Available angiography and duplex sonography data
were used to determine the binary restenosis rate.
Angiograms were also evaluated for LLL and for the
presence of aneurysms or other abnormalities of the
treated arteries.
The conduct of the THUNDER trial and the 5-year
FU evaluation met all local legal and regulatory re-
quirements and were approved by the local ethics
committee at each study site. The study was con-
ducted in accordance with the Declaration of Helsinki
and the International Conference on Harmoniza-
tion guideline. Furthermore, study conduct was in
accordance with sections 40/41 of the German
Drug Act and sections 20 to 22 of the Medical
Devices Act. All patients gave written informed
consent.
SEX COMPARISON AND ANALYSIS OF LESION LENGTH.
Angiographic LLL (difference between the post-
procedural and 6-month FU minimal lumen diam-
eter, evaluated by quantitative angiography) was the
primary endpoint. Data referring to the intervention
and 6-month FU were taken from the analysis pro-
vided by the blinded core lab. Analysis of TLR was
performed up to 5-year FU.
STATISTICAL ANALYSIS. Statistical analysis was
performed using SAS (version 9.2, SAS Institute Inc.,
Cary, North Carolina). In the patients available for
5-year FU, the incidence of ﬁrst TLR overall and
the incidence, intensity, and relationship to study
treatment of serious adverse events (SAE) were
analyzed as categorical or binary data. Data are pre-
sented as relative and absolute frequencies and were
tested for group differences using the Fisher exact
test.
Continuous data are presented as mean  SD and
were tested for group differences using a Wilcoxon
rank sum test.
FIGURE 1 Disposition of Patients at 5-Year FU
Chart presents the original THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries) population and the 5-
year follow-up (FU) disposition. Only control patients and those treated with paclitaxel-coated balloon (PCB) were invited to a 5-year FU visit.
Reasons for not performing the 5-year FU are listed. *1 study site dropped out (7 patients in the control group and 2 patients in the PCB group).
CM ¼ uncoated balloon plus paclitaxel in contrast medium; PCB ¼ paclitaxel-coated balloon; TLR ¼ target lesion revascularization.
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104In case of multiple measurements per patient,
multinomial or logistic regression methods were used
based on generalized estimation equations to account
for correlations between observations within the
same patient. Independence was used as the working
correlation matrix.
For the endpoint TLR, survival analysis was per-
formed for the period from randomization to ﬁrst
event using proportional hazard Cox regression and
log-rank tests. Data are displayed as Kaplan-Meier
curves.
All analyses of the 5-year follow up are descriptive
or exploratory. The follow-up was not included in the
original study protocol.
RESULTS
DISPOSITION OF PATIENTS AT 5-YEAR FU. Five-year
FU was available after 56 months on average (control
group: 56.4  8.6 months; PCB group: 56.1 
10.1 months).According to the exclusion criteria outlined (>1
TLR, femoropopliteal bypass graft involving the
target lesion, and major amputation of the study leg
up to 24-month FU), 16 of 102 patients were not
invited to a 5-year FU visit: 12 of 54 patients (22%)
in the control group and 4 of 48 patients (8%) in the
PCB group. Because 1 study site did not participate
in the 5-year FU, 9 patients were not available for
evaluation at this time (7 patients from the control
group, 2 patients from the PCB group).
Follow-up data at 5 years were obtained from 66
patients (29 patients in the control group and 37 pa-
tients in the PCB group), whereas no data on the
status of the study leg and/or death were available
for a total of 20 of 102 patients (20%) (Figure 1).
With the exception of Rutherford stages, demo-
graphic data, risk factors, and baseline characteris-
tics were well balanced between the 2 groups. At
baseline, 85% of patients in the control group had
Rutherford stage $3 as opposed to a total of 96%
of patients in the PCB group. However, at 5-year
FIGURE 2 Time From the Intervention to the TLR in Patients With TLR
Histogram shows the distribution and the time from the intervention to the TLR in the PCB
and control groups. Median values are presented. Abbreviations as in Figure 1.
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105FU, the results are similar in the both groups. About
57% of patients with available Rutherford assess-
ment have Rutherford stages #2 (Table 1).
CLINICAL RESULTS. Up to the 24-month FU exami-
nation, TLR was performed in 28 of 54 patients in
the control group (52%) versus 8 of 48 patients
treated with PCB (17%, p < 0.001). Between 24-month
and 5-year FU, 7 TLR were performed in 6 of 29
patients of the control group. In the PCB group, 5
TLR were necessary in 3 of 37 patients. Data from
the entire study period show that the cumulative
number of patients with at least 1 TLR was distinctly
lower in the PCB group. In the control group, TLR was
necessary in 30 of 54 of the patients (56%) compared
with 10 of 48 (21%) in the PCB group (p ¼ 0.0005). In
patients with TLR, the time from the intervention to
the TLR was 607 days in the PCB group versus 206
days in the control group (p ¼ 0.04) (Figures 2 and 3);
however, the patients without TLR were not included
in this calculation. The Kaplan-Meier curves for TLR
are shown in Figure 2.
Eight of 54 evaluable patients (15%) died in the
period between the 24-month and 5-year FU: 3 of
24 (12.5%) in the control group and 5 of 35 (16.7 %)
in the PCB group.
Two patients with baseline Rutherford class 5
had major amputations below-the-knee 0.6 andTABLE 1 Rutherford Stage – CRF Data
Control Group PCB Group
Whole study population, N ¼ 102 54 48
Baseline
1 1 (1.9) -
2 7 (13.0) 2 (4.2)
3 39 (72.2) 33 (68.8)
4 1 (1.9) 6 (12.5)
5 6 (11.1) 7 (14.6)
5-year FU population, n ¼ 30 14 16
Baseline
2 1 (7.1) —
3 12 (85.7) 11 (68.8)
4 — 2 (12.5)
5 1 (7.1) 3 (18.8)
5-year FU*
0 4 (28.6) 2 (12.5)
1 3 (21.4) 7 (43.8)
2 1 (7.1) —
3 4 (28.6) 5 (31.3)
4 2 (14.3)
5 – 1 (6.3)
6 – 1 (6.3)
Values are n or n (%). Dashes indicate no patients in this Rutherford stage.
*Data include 3 patients each with previous TLR.
CRF ¼ case report form; FU ¼ follow-up; PCB ¼ paclitaxel-coated balloon.2.4 months after treatment with a PCB. One additional
patient (PCB group, baseline Rutherford class 3) had a
major below-the-knee amputation 11 months after the
study intervention (1). Between 24-month FU and 5-
year FU, 1 above-the-knee amputation (28 months af-
ter the intervention) in a patient of the control group
and 1 major below-the-knee amputation (45 months
after the intervention) in the PCB group were re-
ported. None of the events was classiﬁed as related to
the study device by the investigator.
ANGIOGRAPHY/DUPLEX ULTRASOUND. The primary
endpoint of LLL 6 months after angioplasty was
signiﬁcantly lower in the group treated with PCB than
in the control group (0.4  1.2 mm vs. 1.7  1.8 mm,
p < 0.001) (1). At 12-month FU, mean LLL was deter-
mined in 33 of 48 patients (69%) in the PCB group
and in 36 of 54 patients (67%) in the control group. In
2 patients of the PCB group and in 14 patients of the
control group, TLR was performed prior to 12-month
reangiography. Nevertheless, the statistical compari-
son of the treatment groups resulted in a signiﬁcant
difference in favor of the PCB group versus the con-
trol group (LLL: 0.7  1.5 mm vs. 1.9  1.9 mm, p ¼
0.01). Signiﬁcantly better results (p < 0.05) for the
PCB versus the control group were observed for the
binary restenosis rate at the 6-month (17% vs. 44%)
and 12-month FU (24% vs. 50%).
At 5-year FU, 31 patients consented to an angio-
graphic or duplex ultrasound evaluation of the target
lesion (13 patients in the control group and 18
TABLE 2 LLL, Binary
LLL (mm) Mean 
6-month FU 1.7  1
12-month FU 1.9  1
5-year FU 1.5  1
Binary Restenosis (%)
6-month FU
12-month FU
5-year FU
First TLR (cumulative)
6-month FU
12-month FU
24-month FU
5-year FU
LLL ¼ late lumen loss; TLR
FIGURE 3 Kaplan-Meier Curve of Time Free of TLR
Time free of TLR by treatment group in the course of the study is presented. Median ¼ 206
days in the control group (n ¼ 30) and 607 days in the PCB group (n ¼ 10) (p ¼ 0.04).
Abbreviations as in Figure 1.
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106patients in the PCB group). The control group
included 5 patients who had undergone TLR prior to
reangiography or duplex ultrasound, whereas the PCB
group included only 3 patients after TLR. In this small
group of 31 patients, PCB was associated with a lower
rate of binary restenosis at 5-year FU (3 of 18 [17%]Restenosis, and Cumulative TLR Over the Study Period
Control Group
(n ¼ 54)
PCB Group
(n ¼ 48)
p ValueSD Patients With Data, n Mean  SD Patients With Data, n
.8 48 0.4  1.2 41 0.0007
.9 36
14 with previous TLR
0.7  1.5 33
2 with previous TLR
0.01
.3 11
4 with previous TLR
0.7  1.9 13
1 with previous TLR
0.54
n
% Related to Patients
With Data n
% Related to Patients
With Data p Value
21 43.8 7 17.1 0.01
17 50.0 8 24.2 <0.05
7 54 3 17 0.04
n
Treated Patients,
% (n ¼ 54) n
Treated Patients,
% (n ¼ 48) p-value
20 37.0 2 4.2 <0.0001
26 48.1 5 10.4 <0.0001
28 51.9 8 16.7 0.0003
30 55.6 10 20.8 0.0005
¼ target vessel revascularization; other abbreviations as in Table 1.vs. 7 of 13 [54%], p ¼ 0.04). In the patients with
angiography, there was a statistically not signiﬁcant
difference in LLL (1.5 mm in the control group vs.
0.7 mm in the PCB group, p ¼ 0.54) (Table 2).
Analysis of angiography and ultrasound ﬁndings
as well as SAE revealed no evidence of aneurysm
formation or other vascular abnormalities.
SEX ANALYSIS. In the explorative analysis of these
data there was no difference in LLL at 6-month FU
between women and men in the control (1.61 mm vs.
1.76 mm) and PCB groups (0.37 mm vs. 0.42 mm)
(Figure 4). In contrast, 5 years after treatment with a
PCB, the cumulative TLR rate was lower in men than
in women (4 of 24 patients [17%] vs. 6 of 16 patients
[38%]) (Table 3). The cumulative 5-year TLR rate in
the control group was instead slightly higher for
men (20 of 28 patients [71%] vs. 10 of 19 patients
[52%]) (Table 3).
LESION LENGTH ANALYSIS. There were 18 patients
with target lesion lengths >10 cm (9 patients in the
control group [average lesion length: 19.9 cm] and
9 patients in the PCB group [average lesion length:
17.2 cm]), and 84 patients with a lesion length #10 cm
(39 in the PCB group and 45 in the control group). The
positive effect of the PCB was also observed for
lesions with >10 cm in length: LLL at 6-month FU
as well as the cumulative 5-year TLR rate were in
favor of the PCB (LLL: 1.3 mm and TLR rate: 33%
vs. LLL: 2.6 mm and TLR rate: 75% in the control
group) (Figure 5).
DISCUSSION
The aim of the long-term FU of the THUNDER study
was to assess the clinical efﬁcacy of the PCB
compared with that of the uncoated balloon based on
the number of TLR. In addition, safety was assessed
by analyzing SAE reported in the total patient cohort.
The intention of the angiographic or duplex ultra-
sound FU after 5 years was to detect possible side
effects of PCB, which might not be reﬂected by the
TLR rate (e.g., aneurysms). Because patients with >1
TLR already had several interventions prior to the
5-year FU, they were excluded from this additional
analysis.
The present study was designed to measure
angiographic LLL at 6-month FU and was not pow-
ered to assess angiographic and clinical outcomes
up to 5 years after study intervention. However, the
use of PCB resulted in reduced LLL, binary reste-
nosis, and TLR rate at 5-year FU. Over this period,
the cumulative number of patients with ﬁrst TLR
was distinctly lower in the PCB group than in the
FIGURE 4 Sex Analysis: LLL at 6-Month FU
The histogram presents late lumen loss (LLL) at 6-month FU in
female and male patients. Abbreviations as in Figure 1.
FIGURE 5 Lesion Length Analysis: LLL at 6-Month FU
The histogram presents LLL at 6-month FU in lesions with a
length of 1 to 10 cm and >10 cm. Abbreviations as in Figures 1
and 4.
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107control group. The same applies to the total number
of TLR in the respective treatment groups. Most of
the ﬁrst TLR in the control group were necessary
within the ﬁrst 6 to 8 months after the intervention
(20 of 30 TLR ¼ 67% of TLR), whereas treatment
with a PCB resulted in only 2 of 10 TLR during
this period. These results show that, despite the
very short contact of the PCB with the vessel wall,
paclitaxel inhibits restenosis due to neointimal pro-
liferation in the ﬁrst months after angioplasty.
The beneﬁt persists over the entire study period,
which is reﬂected in the observation that the
low TLR rate at 24-month FU (17% vs. 52%) is
maintained over the 5-year FU period. There is no
increase in the incidence of late TLR in the group
treated with the PCB although treatment with
the coated balloon cannot prevent progression ofTABLE 3 Sex Analysis: Cumulative TLR Over the Study Period
Follow-Up
Control Group PCB Group
Female
(n ¼ 20)
Male
(n ¼ 34)
Female
(n ¼ 17)
Male
(n ¼ 31)
6-month 7 (35) 13 (38) 1 (6) 1 (3)
12-month 9 (45) 17 (50) 3 (18) 2 (6)
24-month 9 (50) 19 (58) 6 (38)* 2 (7)*
5-year 10 (52) 20 (71) 6 (38) 4 (17)
Values are n (% related to available patients/patients with data). *Differences
between sexes are signiﬁcant.atherosclerosis, which ultimately results in similar
TLR rates in both groups.
Using multiple PCB for treating long lesions might
lead to higher local and systemic paclitaxel exposure
and to a higher incidence of adverse events several
years after treatment. However, peak plasma con-
centrations of paclitaxel shortly after the intervention
were found to be below those known to cause sys-
temic side effects (11). No late thrombosis or forma-
tion of aneurysm was recorded in any patient up to
2 years after treatment (1). The incidence of SAE,
major amputation rate, and death at the 5-year FU
did not differ signiﬁcantly between both groups.
Driven by the fact that the patients of the control
group received more frequently more than 1 TLR
during the ﬁrst 24 months after the intervention,
which was a pre-deﬁned exclusion criterion for long-
term FU, only a positive selection of patients were
invited for the 5-year FU examination. This selection
process favored the control group over the PCB group
(Figure 1). Furthermore, in the 5-year FU population
of the control group, approximately 93% of patients
had baseline Rutherford stages #3 (7% with Ruth-
erford 5) compared with 70% of patients in the PCB
group (30% with Rutherford 4 or 5) (Table 1). This
might have affected outcomes and have impacts on
the direct comparison of the 2 groups in terms of
death and amputation rates up to 5-year FU. The
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108results presented here are consistent with the 5-year
FU results of the coronary Paccocath ISR study (9).
Women account for a growing percentage of the
elderly population presenting with peripheral arte-
rial disease. The analysis presented here suggests
that the response to treatment with PCB may be
different in men and women, conﬁrming a tendency
observed in the PACIFIER (Reocclusion Prophylaxis
with Paclitaxel-coated Angioplasty Balloon Catheters
in Atherosclerotic Stenosis and Occlusion of Femo-
ropopliteal Arteries) study (3). Although LLL at 6
months was similar in the PCB group in women and
men, the long-term beneﬁt of coated-balloon treat-
ment appears to be greater in men than women,
although absolute numbers of patients are small.
We found beneﬁcial effects of PCB in the treatment
of femoropopliteal arteries for lesions <10 cm and a
tendency toward a beneﬁt also for longer lesions
compared with correspondingly long lesions in the
control group. However, a statistically signiﬁcant
superiority could not be shown, which is probably
attributable to the smaller number of patients with
lesions >10 cm in length.
PCB used in the THUNDER study were provided
by Bavaria Medizintechnologie, later on marketed
by Bayer HealthCare’s as Cotavance drug-eluting
balloon with Paccocath coating. In 2013, Bayer dis-
continued offering the product on reasons unrelated
to clinical performance. The Paccocath coatingformulation is successfully used in cardiology on
SequentPlease balloons (B. Braun Melsungen).
STUDY LIMITATIONS. This randomized trial was
powered on a 6-month angiographic primary end-
point. The 5-year FU was not prespeciﬁed in the study
protocol. Therefore, the sample size is small for
analysis of endpoints at 5-year FU and for subgroup
analysis regarding sex and lesion length.
CONCLUSIONS
Our 5-year analysis shows that a signiﬁcant technical
beneﬁt regarding LLL of the PCB versus uncoated
balloons persists over 5 years, resulting in a signiﬁ-
cantly lower TLR rate and longer interval to reinter-
vention in the PCB cohort. At the same time, this
analysis has identiﬁed no signs of drug-related local
vessel abnormality.
ACKNOWLEDGMENTS The authors thank Maren
Kutschera and Carsten Schwenke for their contri-
bution to the evaluation and statistical analysis
of data.
REPRINT REQUESTS AND CORRESPONDENCE: Prof.
Dr. Gunnar Tepe, Institute for Diagnostic and In-
terventional Radiology, RoMed Clinic Rosenheim,
Pettenkoferstrasse 10, 83022 Rosenheim, Germany.
E-mail: gunnar.tepe@ro-med.de.RE F E RENCE S1. Tepe G, Zeller T, Albrecht T, et al. Local delivery
of paclitaxel to inhibit restenosis during angio-
plasty of the leg. N Engl J Med 2008;358:689–99.
2. Werk M, Langner S, Reinkensmeier B, et al.
Inhibition of restenosis in femoropopliteal
arteries: paclitaxel-coated versus uncoated
balloon: femoral paclitaxel randomized pilot trial.
Circulation 2008;118:1358–65.
3. Werk M, Albrecht T, Meyer DR, et al.
Paclitaxel-coated balloons reduce restenosis
after femoro-popliteal angioplasty: evidence from
the randomized PACIFIER trial. Circ Cardiovasc
Interv 2012;5:831–40.
4. Fanelli F, CannavaleA, Boatta E, et al. Lower limb
multilevel treatmentwithdrug-elutingballoons: 6-
month results from the DEBELLUM randomized
trial. J Endovasc Ther 2012;19:571–80.
5. Scheinert D, Duda S, Zeller T, et al. The
LEVANT I (Lutonix Paclitaxel-Coated Balloon
for the Prevention of FemoropoplitealRestenosis) trial for femoropopliteal revascu-
larization: ﬁrst-in-human randomized trial of
low-dose drug-coated balloon versus uncoated
balloon angioplasty. J Am Coll Cardiol Intv
2014;7:10–9.
6. Micari A, Cioppa A, Vadalà G, et al. Clinical
evaluation of a paclitaxel-eluting balloon
for treatment of femoropopliteal arterial disease:
12-month results from a multicenter Italian
registry. J Am Coll Cardiol Intv 2012;5:331–8.
7. Cioppa A, Stabile E, Popusoi G, et al. Combined
treatment of heavy calciﬁed femoro-popliteal
lesions using directional atherectomy and a
paclitaxel coated balloon: one-year single centre
clinical results. Cardiovasc Revasc Med 2012;13:
219–23.
8. Micari A, Cioppa A, Vadalà G, et al. 2-year results
of paclitaxel-eluting balloons for femoropopliteal
artery disease: evidence from a multicenter regis-
try. J Am Coll Cardiol Intv 2013;6:282–9.9. Scheller B, Clever YP, Kelsch B, et al. Long-
term follow-up after treatment of coronary in-
stent restenosis with a paclitaxel-coated
balloon catheter. J Am Coll Cardiol Intv 2012;5:
323–30.
10. Scheller B, Speck U, Abramjuk C,
Bernhardt U, Böhm M, Nickenig G. Paclitaxel
balloon coating, a novel method for prevention
and therapy of restenosis. Circulation 2004;110:
810–4.
11. Freyhardt P, Zeller T, Kröncke TJ, et al. Plasma
levels following application of paclitaxel-coated
balloon catheters in patients with stenotic or
occluded femoropopliteal arteries. Rofo 2011;183:
448–55.KEY WORDS angioplasty, drug-coated
balloon, femoral artery, long-term outcome,
paclitaxel, peripheral arterial disease
